Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03348423 · ClinicalTrials.gov registry record · Phase 2
Evaluation of DEX-IN During Outpatient Procedures
A Phase 2 study, sponsored by Baudax Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT03348423 is a Phase 2 study that has completed, run by Baudax Bio. The registered enrollment target is 45 participants.
The verdict
NCT03348423, a Phase 2 study, has completed, sponsored by Baudax Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the analgesic efficacy of DEX-IN compared with placebo and active control (fentanyl), in subjects undergoing painful outpatient and office based procedures.
Interventions
- DRUG Placebo
- DRUG Fentanyl
- DRUG DEX-IN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2018-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03348423
The ClinicalTrials.gov registry entry for NCT03348423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baudax Bio, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03348423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03348423 about?
NCT03348423 is a clinical study titled "Evaluation of DEX-IN During Outpatient Procedures". The primary objective of this study is to evaluate the analgesic efficacy of DEX-IN compared with placebo and active control (fentanyl), in subjects undergoing painful outpatient and office based procedures.
What is the current status of trial NCT03348423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2017-11-15. Estimated completion is 2018-01-18.
What interventions are being tested in trial NCT03348423?
The interventions under investigation include: Placebo (DRUG), Fentanyl (DRUG), DEX-IN (DRUG).
Who is sponsoring clinical trial NCT03348423?
This trial is sponsored by Baudax Bio, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.